Key result
Most newer circulating biomarkers are not ready for routine clinical use in primary prevention, whereas traditional risk factors continue to perform well for predicting future cardiovascular risk.
Traditional cardiovascular risk factors remain the most reliable tools for predicting future risk, as most novel biomarkers currently lack clinical utility for primary prevention.
No takes yet. Share an insight, caveat, or question.
Traditional risk factors should guide primary prevention; leaves open clinical utility of newer biomarkers pending further validation.
Thomas J. Wang (2008) conducted a review in Cardiovascular disease. New cardiovascular risk factors and circulating biomarkers vs. Traditional risk factors was evaluated. Most newer circulating biomarkers are not ready for routine clinical use in primary prevention, whereas traditional risk factors continue to perform well for predicting future cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: